(MENAFN- IMARC Group)
According to IMARC Group latest report titled“ Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032 ”, offers a comprehensive analysis of the industry, which comprises insights on depression drugs market share . The report also includes competitor and regional analysis, and contemporary advancements in the global market.
The global depression drugs market size reached US$ 18.6 Billion in 2023 . Looking forward, IMARC Group expects the market to reach US$ 24.6 Billion by 2032 , exhibiting a growth rate (CAGR) of 3.1% during 2024-2032.
Request a Free Sample Report: /depression-drugs-market/requestsample
Depression drugs are medications used to treat major depressive disorder and other mood disorders. These drugs work by balancing chemicals in the brain, primarily neurotransmitters, such as serotonin, norepinephrine, and dopamine, which influence mood and emotional responses. There are several types of depression drugs, each working differently based on their chemical structure and impact on the brain. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed due to their relative safety and lower side effect profile. They increase the level of serotonin in the brain, a neurotransmitter associated with feelings of well-being and happiness. Examples include fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa).
The increasing prevalence of depression worldwide, attributed to various socio-economic and lifestyle factors, is driving the global market. Stressful lifestyles, rising incidences of chronic diseases, and genetic predispositions are contributing significantly to this trend. The global burden of mental health disorders, especially depression, is catalyzing the demand for effective treatment options, thereby fueling the market growth. Furthermore, continual advancement in medical research and pharmaceuticals. The development of novel antidepressants with fewer side effects and better efficacy is encouraging more individuals to seek treatment. This is particularly relevant in the context of growing awareness and social acceptance of mental health issues. Public health campaigns and initiatives by governments and NGOs are playing a crucial role in de-stigmatizing mental health conditions, leading to increased diagnosis and treatment rates.
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players operating in the market.
Otsuka Pharmaceutical Pfizer Eli Lilly and Company AstraZeneca Novartis Bristol-Myers Squibb GlaxoSmithKline Takeda Pharmaceutical Company Allergan, Johnson & Johnson Zhejiang NHU Company Ltd Sebela Pharmaceuticals
Key Market Segmentation:
Our report has categorized the market based on region, drug class, disorder type, drug type and distribution channel.
Breakup by Drug Class:
Atypical Antipsychotics Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Selective Serotonin Reuptake Inhibitors (SSRIs) Central Nervous System (CNS) Stimulants Tricyclic Antidepressants Monoamine Oxidase Inhibitors Others
Breakup by Disorder Type:
Major Depressive Disorder Obsessive-Compulsive Disorder Generalized Anxiety Disorder Panic Disorder Others
Breakup by Drug Type:
Generic Drugs Branded Drugs
Breakup by Distribution Channel:
Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
Breakup by Region:
North America (United States, Canada) Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Asia Pacific (China, Japan, India, Australia, Indonesia, South Korea, Others) Latin America (Brazil, Mexico, Others) Middle East and Africa
Key Highlights of the Report:
Market Performance (2018-2023) Market Outlook (2024-2032) Porter's Five Forces Analysis Market Drivers and Success Factors SWOT Analysis Value Chain Comprehensive Mapping of the Competitive Landscape
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: --
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
MENAFN06022024004122016232ID1107816468
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.